Literature DB >> 25190656

Developing the impact of Vision Impairment-Very Low Vision (IVI-VLV) questionnaire as part of the LoVADA protocol.

Robert P Finger1, Betty Tellis1, Julie Crewe2, Jill E Keeffe1, Lauren N Ayton1, Robyn H Guymer1.   

Abstract

PURPOSE: To design and evaluate an instrument appropriate for assessing vision-related quality of life (VRQoL) in persons with severe vision loss.
METHODS: A total of 603 legally blind persons (better eye visual acuity of <20/200) were interviewed using an item pool based on the original Impact of Vision Impairment (IVI) questionnaire, augmented by items appropriate for persons with severe vision loss. Refinement and item reduction was done in three steps using factor and Rasch analysis to assess psychometric properties, exploring key indices, such as response category functioning (floor and ceiling effects), instrument unidimensionality, discriminant ability, and targeting of item difficulty to patient ability.
RESULTS: A final pool of 28 items was selected that grouped into two subscales of the IVI-VLV: activities of daily living, mobility, and safety (ADLMS; 16 items) and emotional well-being (EWB; 12 items). Both subscales are unidimensional, able to differentiate reliably between at least three different levels of VRQoL, and item difficulty was adequate for the assessed sample. Using generalized linear models and controlling for age, we found that only poor general health (P = 0.005 and P = 0.007) and concurrent depression and anxiety (P = 0.019 and P < 0.001) were associated with a lower ADLMS and EWB subscale score, respectively.
CONCLUSIONS: The IVI-VLV is a valid and reliable VRQoL measure in persons with severe vision loss, and its measurement is almost unaffected by participants' self-perceived general or mental health. The IVI-VLV can be used as an outcome measure in trials attempting sight restoration. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  psychometric measurement; quality of life; questionnaire development; severe vision impairment

Mesh:

Year:  2014        PMID: 25190656     DOI: 10.1167/iovs.14-14731

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

1.  Optimizing measurement of vision-related quality of life: a computerized adaptive test for the impact of vision impairment questionnaire (IVI-CAT).

Authors:  Eva K Fenwick; Bao Sheng Loe; Jyoti Khadka; Ryan E K Man; Gwyn Rees; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2019-11-09       Impact factor: 4.147

2.  Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce.

Authors:  Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk
Journal:  Transl Vis Sci Technol       Date:  2020-07-16       Impact factor: 3.283

Review 3.  Patient-Centered Outcome Measures to Assess Functioning in Randomized Controlled Trials of Low-Vision Rehabilitation: A Review.

Authors:  Joshua R Ehrlich; George L Spaeth; Noelle E Carlozzi; Paul P Lee
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

Review 4.  An update on retinal prostheses.

Authors:  Lauren N Ayton; Nick Barnes; Gislin Dagnelie; Takashi Fujikado; Georges Goetz; Ralf Hornig; Bryan W Jones; Mahiul M K Muqit; Daniel L Rathbun; Katarina Stingl; James D Weiland; Matthew A Petoe
Journal:  Clin Neurophysiol       Date:  2019-12-10       Impact factor: 3.708

5.  First-in-human trial of a novel suprachoroidal retinal prosthesis.

Authors:  Lauren N Ayton; Peter J Blamey; Robyn H Guymer; Chi D Luu; David A X Nayagam; Nicholas C Sinclair; Mohit N Shivdasani; Jonathan Yeoh; Mark F McCombe; Robert J Briggs; Nicholas L Opie; Joel Villalobos; Peter N Dimitrov; Mary Varsamidis; Matthew A Petoe; Chris D McCarthy; Janine G Walker; Nick Barnes; Anthony N Burkitt; Chris E Williams; Robert K Shepherd; Penelope J Allen
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

6.  Optimizing the ULV-VFQ for Clinical Use Through Item Set Reduction: Psychometric Properties and Trade-Offs.

Authors:  Gislin Dagnelie; Pamela E Jeter; Olukemi Adeyemo
Journal:  Transl Vis Sci Technol       Date:  2017-05-31       Impact factor: 3.283

7.  Development of the Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ).

Authors:  Pamela E Jeter; Collin Rozanski; Robert Massof; Olukemi Adeyemo; Gislin Dagnelie
Journal:  Transl Vis Sci Technol       Date:  2017-05-31       Impact factor: 3.283

8.  Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis.

Authors:  Jacque L Duncan; Thomas P Richards; Aries Arditi; Lyndon da Cruz; Gislin Dagnelie; Jessy D Dorn; Allen C Ho; Lisa C Olmos de Koo; Pierre-Olivier Barale; Paulo E Stanga; Gabriele Thumann; Yizhong Wang; Robert J Greenberg
Journal:  Clin Exp Optom       Date:  2016-08-25       Impact factor: 2.742

9.  The Impact of Vision Impairment (IVI) Questionnaire; Validation of the Thai-Version and the Implementation on Vision-Related Quality of Life in Thai Rural Community.

Authors:  Mansing Ratanasukon; Jongjit Tongsomboon; Patama Bhurayanontachai; Pichai Jirarattanasopa
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

10.  Living with Ultra-Low Vision: An Inventory of Self-Reported Visually Guided Activities by Individuals with Profound Visual Impairment.

Authors:  Olukemi Adeyemo; Pamela E Jeter; Collin Rozanski; Ellen Arnold; Lauren A Dalvin; Bonnielin Swenor; Gislin Dagnelie
Journal:  Transl Vis Sci Technol       Date:  2017-05-31       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.